Berger Y - Search Results

1

Amiodarone and N-desethylamiodarone concentrations in plasma, red blood cells, and myocardium after a single oral dose: relation to hemodynamic effects in surgical patients.

Escoubet B, Jaillon P, Berger Y, Commin P, Menasché P, Piwnica A, Echter E. Escoubet B, et al. Among authors: berger y. Am Heart J. 1986 Feb;111(2):280-5. doi: 10.1016/0002-8703(86)90140-7. Am Heart J. 1986. PMID: 3946169 Clinical Trial.

2

[Acute amiodarone poisoning. Clinical and pharmacokinetic study].

Bouffard Y, Berger Y, Delafosse B, Matteazzi JR, Guillaume C, Tournadre P, Perrot D, Motin J. Bouffard Y, et al. Among authors: berger y. Arch Mal Coeur Vaiss. 1985 Jan;78(1):130-2. Arch Mal Coeur Vaiss. 1985. PMID: 3919673 French.

3

Absolute bioavailability of amiodarone in normal subjects.

Pourbaix S, Berger Y, Desager JP, Pacco M, Harvengt C. Pourbaix S, et al. Among authors: berger y. Clin Pharmacol Ther. 1985 Feb;37(2):118-23. doi: 10.1038/clpt.1985.22. Clin Pharmacol Ther. 1985. PMID: 3967454

4

[Acute amiodarone poisoning. Clinical and pharmacokinetic study].

Bouffard Y, Berger Y, Delafosse B. Bouffard Y, et al. Among authors: berger y. Arch Mal Coeur Vaiss. 1985 Oct;78(10):1589-90. Arch Mal Coeur Vaiss. 1985. PMID: 3938226 French. No abstract available.

5

Pharmacokinetic profile and bioavailability of a new galenic formulation of ticlopidine.

Desager JP, van Nieuwenhuyze Y, Dricot J, Berger Y, Harvengt C. Desager JP, et al. Among authors: berger y. Int J Clin Pharmacol Res. 1990;10(4):247-50. Int J Clin Pharmacol Res. 1990. PMID: 2079383

6

Plasma levels and pharmacokinetics of single and multiple dose of tetrazepam in healthy volunteers.

Bun H, Philip F, Berger Y, Necciari J, Al-Mallah NR, Serradimign A, Cano JP. Bun H, et al. Among authors: berger y. Arzneimittelforschung. 1987 Feb;37(2):199-202. Arzneimittelforschung. 1987. PMID: 2883980

7

New approach in bioavailability study of two formulations of ethyl loflazepate.

Ba BB, Iliadis A, Durand A, Berger Y, Cano JP. Ba BB, et al. Among authors: berger y. Arzneimittelforschung. 1988 Oct;38(10):1486-9. Arzneimittelforschung. 1988. PMID: 2904268

8

Effect of renal failure on the pharmacokinetics of ethyl loflazepate (Victan) in man.

Ba BB, Iliadis A, Durand A, Berger Y, Necciari J, Cano JP. Ba BB, et al. Among authors: berger y. Fundam Clin Pharmacol. 1989;3(1):11-7. doi: 10.1111/j.1472-8206.1989.tb00025.x. Fundam Clin Pharmacol. 1989. PMID: 2714728

9

Human hepatocytes as a key in vitro model to improve preclinical drug development.

Fabre G, Combalbert J, Berger Y, Cano JP. Fabre G, et al. Among authors: berger y. Eur J Drug Metab Pharmacokinet. 1990 Apr-Jun;15(2):165-71. doi: 10.1007/BF03190200. Eur J Drug Metab Pharmacokinet. 1990. PMID: 2200686 Review.

10

Quantitative high-performance liquid chromatographic, gas chromatographic, and gas chromatographic-mass spectrometric analysis of ticlopidine in baboon plasma after solid-phase extraction.

Arnoux P, Sales Y, Mandray M, Lechat P, Berger Y, Cano JP. Arnoux P, et al. Among authors: berger y. J Pharm Sci. 1991 Nov;80(11):1092-5. doi: 10.1002/jps.2600801119. J Pharm Sci. 1991. PMID: 1815063

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

178 results

Search Page

Filters